UCSF 21st Annual Osteoporosis New Insights in Research, Diagnosis, and Clinical Care 2024

Include: 4 videos 12 pdfs, size: 12.6 GB
Target Audience: osteoporosis for physicians

Description

Include: 4 videos 12 pdfs, size: 12.6 GB

Now in its 21st year, and presented by the Department of Epidemiology and Biostatistics of the University of California, San Francisco School of Medicine, this 1-day virtual course features an expert faculty that will discuss the epidemiology, pathophysiology, diagnosis, and treatment of osteoporosis. The course will critically review current treatment options. There will be an emphasis on recent developments and current controversies in the etiology, diagnosis, and management of osteoporosis.

The course will provide an update on current recommendations about screening and treatment of osteoporosis for physicians and other clinicians working with osteoporosis patients. It will also benefit researchers, technologists, and pharmaceutical or device company professionals who would find additional scientific background in the disease helpful. No prior clinical or scientific training in osteoporosis is required.

Objectives

Screen for and diagnose osteoporosis according to the latest evidence-based standards of care;
Interpret dual-energy X-ray absorptiometry (DXA) bone density scans and avoid common DXA pitfalls;
Provide appropriate pharmacological treatment for osteoporosis, including antiresorptive and anabolic therapies;
Assess the benefits and risks of continuing long-term antiresorptive osteoporosis therapy and determine optimal treatment duration;
Understand the evidence for vitamin D in the optimization of bone health;
Recognize racial differences and disparities in osteoporosis care.

Course Outline

All program times listed are in Pacific Time Zone.

Thursday, July 25, 2024
SCREENING AND DIAGNOSIS
8:00 AM		Zoom Registration and login, housekeeping, overview
8:10	G	Osteoporosis Screening and Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis	Steven T. Harris, MD, FACP, FASBMR
8:50		Q&A
ANTIRESORPTIVE TREATMENT
9:00	G	Bisphosphonate Efficacy, Duration, and Drug Holidays: Maximize Benefits and Minimize Risk	Dennis M. Black, PhD
9:30		Q&A
9:40	G	Long-Term Treatment With and Following Denosumab	Karin Y. Wu, MD
10:10		Q&A
10:20		Break
ANABOLIC TREATMENT
10:35	G	Anabolic Agents: Mechanism, Efficacy, and Safety, and incorporation into Treatment Regimens	Anne L. Schafer, MD
11:05		Q&A
11:15	G	Racial Differences and Disparities in Osteoporosis Care	Nicole C. Wright, PhD, MPH
11:45		Q&A
11:55 AM		Lunch Break
SPECIAL TOPICS IN OSTEOPOROSIS
12:50 PM	G	Exercise for Fall and Fracture Prevention	Lora Giangregorio, PhD
1:20		Q&A
1:30	G	CKD and Skeletal Health	Deborah E. Sellmeyer, MD
2:10		Q&A
2:20		Rare Bone Disease	Yasaman Motlaghzadeh, MD
2:45		Q&A
2:55		Break
3:10	G	DXA Interpretation and Pitfalls	Deborah Sellmeyer, MD
3:40		Q&A
3:50	G	Clinical Roundtable: Q&A with a Panel of Physicians	Dolores M. Shoback, MD Steven T. Harris, MD, FACP, FASBMR Deborah E. Sellmeyer, MD Anne L. Schafer, MD (facilitator)
4:30		Adjourn

Topics:

*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Course Outline section above

00_Introduction-2.pdf
00_Program.pdf
01_HARRIS_Screening and Diagnosis BMD FRAX and Assessment.pdf
02_BLACK_Bisphosphonate.pdf
03_WU_Long-Term Treatment With Denosumab.pdf
04_SCHAFER_Anabolic Agents.pdf
05_WRIGHT_Racial and Ethnic Disparities.pdf
06_GIANGREGORIO_Exercise for Fracture and Fall Prevention.pdf
07_SELLMEYER_Chronic Kidney Disease.pdf
08_MOTLAGHZADEH_Rare Causes of Metabolic Bone Disease.pdf
09_SELLMEYER_DXA Interpretation.pdf
July 25 AM Session Part 1.mp4 (3 hours)
July 25 AM Session Part 2.mp4 (1 hours)
July 25 PM Session Part 1.mp4 (3 hours)
July 25 PM Session Part 2.mp4 (1 hours)
MEP25001_Combined_Syllabus.pdf

UCSF 21st Annual Osteoporosis New Insights in Research, Diagnosis, and Clinical Care 2024

Related products

Login